Answers are grounded in this paper and cite their sources.
Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.
No takes yet. Share an insight, caveat, or question.
Richardson et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: